The IC-50-time evolution is a new model to improve drug responses consistency of large scale studies

Abstract

Abstract: Large-scale studies combining hundreds of cancer cell lines and many cancer drugs, with their promises and challenges, represent a new development in the in vitro screening of cancer drugs. However, drugs sensitivity results of the same cancer cell lines exposed to the same cancer drugs generated different IC50s by these studies as noticed by Haibe-Kains B et al (1). These inconsistencies are due to many factors: the experimental conditions and the use of the Four Parameter Logistic (4PL) regression model to analyze drugs sensitivity results. A new model based on the Levasseur LM et al model, the Gompertzian growth model of in vitro monolayer culture, and the IC-50 time course evolution is more appropriate to improve the accuracy of these large scale studies.